Iron chelation, quo vadis?

Current Opinion in Chemical Biology

Volumn 11, Issue 4, 2007, Pages 419-423

  Nick, Hanspeter ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; CHOLYLHYDROXAMIC ACID; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; DEFERRIFERRITHIOCIN; DIHYDROXYBENZOIC ACID; PYRIDOXAL ISONICOTINOYLHYDRAZONE; UNCLASSIFIED DRUG;

COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TARGETING; ERYTHROCYTE TRANSFUSION; GENE MUTATION; GENETIC ASSOCIATION; HEMOCHROMATOSIS; HUMAN; IRON CHELATION; IRON DEPLETION; IRON KINETICS; IRON OVERLOAD; MOLECULAR WEIGHT; MONOTHERAPY; PATHOGENESIS; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION;

ADMINISTRATION, ORAL; BIOLOGICAL TRANSPORT; DEFEROXAMINE; HEMOCHROMATOSIS; HUMANS; IONS; IRON CHELATING AGENTS;

EID: 34548132409     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2007.04.025     Document Type: Review

References (35)

1. Birch N., Wang X., and Chong H.-S. Iron chelators as therapeutic iron depletion agents. Expert Opin Ther Patents 16 (2006) 1533-1556. This report describes clinically used iron chelators including desferrioxamine, deferasirox, deferiprone (iron overload), dexrazoxane (protection from cardiotoxicity), ciclopirox (antifungal), and iron chelators in the preclinical stage of development, as well as the patent status of these compounds.
2. Alla V., and Bonkovsky H.L. Iron in nonhemochromatotic liver disorders. Semin Liver Dis 25 (2005) 461-472. The authors emphasize the comorbid role of iron in liver diseases such as porphyria cutanea tarda, alcoholic liver disease, nonalcoholic steatohepatitis, and chronic hepatitis C.
3. Pomarede R., Girot R., Constant S., and Rappaport R. Effect of hematologic treatment on the growth and puberty of children with thalassemia major. Arch Fr Pediatr 41 (1984) 255-259
4. Wolman I.J. Transfusion therapy in Cooley's anemia: growth and health as related to long-range haemoglobin levels. A progress report. Ann NY Acad Sci 119 (1964) 736-747
5. Modell B., and Berdoukas V. The Clinical Approach to Thalassemia (1984), Grune and Stratton (Harcourt Brace Jovanovich, Publishers), London
6. Propper R.D., Shurin S.B., and Nathan D.G. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 294 (1976) 1421-1423
7. Vichinsky E.P., MacKlin E.A., Waye J.S., Lorey F., and Olivieri N.F. Changes in the epidemiology of thalassemia in North America: a new minority disease. Pediatrics 116 (2005) e818-e825
8. Peterson C.M., Graziano J.H., Grady R.W., Jones R.L., Vlassara H.V., Canale V.C., Miller D.R., and Cerami A. Chelation studies with 2,3-dihydroxybenzoic acid in patients with beta-thalassaemia major. Br J Haematol 33 (1976) 477-485
9. Peterson C.M., Grady R.W., Jones R.L., Cerami A., Graziano J.H., Markenson A.L., Lavi U., Canale V., Gray G.F., and Miller D.R. 2,3-DHB ineffective in treatment of iron overload. N Engl J Med 297 (1977) 1404
10. Grady R.W., Graziano J.H., White G.P., Jacobs A., and Cerami A. The development of new iron-chelating drugs, II. J Pharmacol Exp Ther 205 (1978) 565-575
11. Hoy T., Humphrys J., Jacobs A., Williams A., and Ponka P. Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. Br J Haematol 43 (1979) 443-449
12. Richardson D.R., and Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med 131 (1998) 306-315
13. Zähner H., and Nägeli H. Ferrithiocin. Helv Chim Acta 63 (1980) 1400
14. Hider RC, Kontoghiorghes GJ, Silver J: UK Patent GB-2118176 1982.
15. Kontoghiorghes G.J., Aldouri M.A., Sheppard L., and Hoffbrand A.V. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1 (1987) 1294-1295
16. Kontoghiorghes G.J., Aldouri M.A., Hoffbrand A.V., Barr J., Wonke B., Kourouclaris T., and Sheppard L. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Br Med J 295 (1987) 1509-1512
17. Acklin P. A molecular mechanics approach for the prediction of the geometry of high spin Fe(III) complexes with oxygen and nitrogen as coordinating atoms. Helv Chim Acta 83 (2000) 677-686
18. Nick H., Acklin P., Lattmann R., Buehlmayer P., Hauffe S., Schupp J., and Alberti D. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10 (2003) 1065-1076
19. Nisbet-Brown E., Olivieri N.F., Giardina P.J., Grady R.W., Neufeld E.J., Sechaud R., Krebs-Brown A.J., Anderson J.R., Alberti D., Sizer K.C., and Nathan D.G. Randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361 (2003) 1597-1602. This article is a clinical trial with deferasirox to assess net iron excretion (iron balance study) at doses of 10, 20, and 40 mg/kg.
20. Piga A., Galanello R., Forni G.L., Cappellini M.D., Origa R., Zappu A., Donato G., Bordone E., Lavagetto A., Zanaboni L., et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91 (2006) 873-880
21. Shashaty G., Frankewich R., Chakraborti T., Choudary J., Al-Fayoumi S., Kacuba A., Castillo S., Robie-Suh K., Rieves D., Weiss K., and Pazdur R. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology 20 (2006) 1799-1806, 1811; discussion 1811-1813, 1817
22. Kattamis A., Ladis V., Berdousi H., Kelekis N.L., Alexopoulou E., Papasotiriou I., Drakaki K., Kaloumenou I., Galani A., and Kattamis C. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol Dis 36 (2006) 21-25
23. Blake D.R., Winyard P., Lunec J., Williams A., Good P.A., Crewes S.J., Gutteridge J.M., Rowley D., Halliwell B., and Cornish A. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 56 (1985) 345-355
24. Hershko C., Konijn A.M., Nick H.P., Breuer W., Cabantchik Z.I., and Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 97 (2001) 1115-1122
25. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI: Selective iron chelation in Friedreich ataxia. Biological and clinical implications. Blood 2007, March 22 [Epub ahead of print].
26. Pietrangelo A. Hereditary hemochromatosis. Biochim Biophys Acta 1763 (2006) 700-710
27. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106 (2005) 3710-3717. This article is a concise review of the hereditary hemochromatosis disorders due to mutations in HFE, hemojuvelin, hepcidin, transferrin receptor 1, and ferroportin, emphasizing the central role of hepcidin for iron homeostasis.
28. Waalen J., and Beutler E. Hereditary hemochromatosis: screening and management. Curr Hematol Rep 5 (2006) 34-40
29. Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., Aydinok Y., Kattamis A., Kilinc Y., Porter J., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 107 (2006) 3455-3462
30. Yu Y., Wong J., Lovejoy D.B., Kalinowski D.S., and Richardson D.R. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12 (2006) 6876-6883
31. Brittenham G.M. Iron chelators and iron toxicity. Alcohol 30 (2003) 151-158
32. Spellberg B., Edwards Jr. J., and Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18 (2005) 556-569
33. Richardson D.R. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann NY Acad Sci 1012 (2004) 326-341
34. Reed C., Ibrahim A., Edwards Jr. J.E., Walot I., and Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 50 (2006) 3968-3969. This article is a case report describing the astounding recovery of a patient from a deadly fungal infection after short-term administration of deferasirox.
35. Whitnall M., and Richardson D.R. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 13 (2006) 186-197. The authors describe the potential role of iron in Huntington disease, Alzheimer's disease, Parkinson's disease, and Friedreich's ataxia.